Compare FTAIN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
| Metric | FTAIN | MDWD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Israel |
| Employees | 580 | N/A |
| Industry | Misc Corporate Leasing Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | FTAIN | MDWD |
|---|---|---|
| Price | $25.35 | $18.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | N/A | ★ 93.0K |
| Earning Date | N/A | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | N/A | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | N/A | $14.14 |
| 52 Week High | N/A | $22.51 |
| Indicator | FTAIN | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 55.76 |
| Support Level | $25.29 | $18.55 |
| Resistance Level | $25.47 | $19.05 |
| Average True Range (ATR) | 0.14 | 0.57 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 39.23 | 66.25 |
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.